We are live on ! Find out more
GC

Grimes & Company Portfolio holdings

AUM $4.62B
1-Year Est. Return 29.71%
This Fund
S&P 500
This Quarter Est. Return
-3.81%
1 Year Est. Return
+29.71%
3 Year Est. Return
+66.17%
5 Year Est. Return
+73.59%
10 Year Est. Return
+287.64%
AUM
$1.92B
AUM Growth
-$67M
Cap. Flow
+$27.4M
Cap. Flow %
1.43%
Top 10 Hldgs %
52.07%
Holding
283
New
10
Increased
164
Reduced
68
Closed
12

Sector Composition

Rank Sector Weight
1 Miscellaneous 57.4%
2 Technology 12.26%
3 Healthcare 8.63%
4 Financials 5.96%
5 Industrials 4.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IWS icon
251
iShares Russell Mid-Cap Value ETF
IWS
$15B
$211K 0.01%
2,202
+1
+0% +$107
CAT icon
252
Caterpillar
CAT
$360B
$209K 0.01%
1,274
-17
-1% -$3.1K
VBIV
253
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$204K 0.01%
9,630
+116
+1% +$3.13K
IWB icon
254
iShares Russell 1000 ETF
IWB
$48.2B
$202K 0.01%
+1,024
New +$225K
VLO icon
255
Valero Energy
VLO
$116B
$202K 0.01%
+1,894
New +$208K
CLM icon
256
Cornerstone Strategic Value Fund
CLM
$1.96B
$183K 0.01%
+21,656
New +$206K
HBAN icon
257
Huntington Bancshares
HBAN
$32B
$175K 0.01%
13,305
+1,275
+11% +$17K
AVEO
258
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$159K 0.01%
19,380
VLY icon
259
Valley National Bancorp
VLY
$7.48B
$157K 0.01%
14,500
+2,000
+16% +$23.1K
CRF
260
Cornerstone Total Return Fund
CRF
$1.03B
$132K 0.01%
+16,626
New +$152K
ADMA icon
261
ADMA Biologics
ADMA
$1.99B
$130K 0.01%
53,314
INVA icon
262
Innoviva
INVA
$1.53B
$130K 0.01%
11,235
+309
+3% +$4.24K
ISPC icon
263
iSpecimen
ISPC
$3.45M
$108K 0.01%
82
+4
+5% +$7.16K
MRSN
264
DELISTED
Mersana Therapeutics
MRSN
$103K 0.01%
607
+10
+2% +$1.63K
NAK
265
Northern Dynasty Minerals
NAK
$697M
$78K ﹤0.01%
318,950
HRTX icon
266
Heron Therapeutics
HRTX
$60.3M
$67K ﹤0.01%
15,760
+224
+1% +$877
FUBO icon
267
FuboTV Inc
FUBO
$320M
$36K ﹤0.01%
833
ITRM
268
DELISTED
Iterum Therapeutics
ITRM
$24K ﹤0.01%
14,641
+2,681
+22% +$8.14K
RBBN icon
269
Ribbon Communications
RBBN
$293M
$22K ﹤0.01%
10,030
OTLK icon
270
Outlook Therapeutics
OTLK
$165M
$12K ﹤0.01%
500
OGEN icon
271
Oragenics
OGEN
$2.26M
$3K ﹤0.01%
+7
New +$4.09K
ABNB icon
272
Airbnb
ABNB
$98.8B
-4,294
Closed -$383K
EXC icon
273
Exelon
EXC
$43.7B
-4,667
Closed -$212K
EZU icon
274
iShare MSCI Eurozone ETF
EZU
$9.58B
-5,891
Closed -$214K
FLOT icon
275
iShares Floating Rate Bond ETF
FLOT
$10.8B
-6,988
Closed -$349K

Similar funds

Grimes & Company's Q3 2022 Portfolio in Review

As of Q3 2022, Grimes & Company held 283 positions worth $1.92B, down 3.4% from $1.98B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Grimes & Company's Q3 2022 filing shows 10 new, 164 increased, 68 reduced and 12 closed positions. Its largest new stake was State Street Communication Services Select Sector SPDR ETF: 76,532 shares worth $3.67M. The largest sale was iShares 0-1 Year Treasury Bond ETF, an estimated $33.1M.

By sector, the portfolio is most concentrated in Miscellaneous at 57% of assets, up from 57% a quarter earlier, followed by Technology and Healthcare.

  • Grimes & Company's largest Q3 2022 buy was State Street Communication Services Select Sector SPDR ETF: 76,532 shares worth $3.67M.
  • Grimes & Company added most to iShares Russell 2000 ETF in Q3 2022, an estimated $79.2M increase.
  • Grimes & Company's biggest Q3 2022 reduction was iShares 0-1 Year Treasury Bond ETF, cutting an estimated $33.1M.
  • Grimes & Company fully exited State Street Consumer Staples Select Sector SPDR ETF in Q3 2022, selling an estimated $22.1M.
  • Grimes & Company's ten largest holdings make up 52% of its $1.92B portfolio in Q3 2022.
  • Grimes & Company opened 10 new positions and closed 12 in Q3 2022.
  • Grimes & Company's portfolio value fell 3.4% quarter-over-quarter to $1.92B.

Based on Grimes & Company's 13F filing for Q3 2022, filed 28 Oct 2022.